Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SM17 in Moderate to Severe Atopic Dermatitis (Phase II, Dose-Finding)
ChiCTR2600120808Phase 2Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Mar 2026
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SM17 in atopic dermatitis (AD) (7 arms), sponsored by Peking University People's Hospital. Primary endpoint: Primary – Percentage change from baseline in Eczema Area and Severity Index (EASI) at Week 16. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
SM17
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on ChiCTR2600120808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600120808.